Synairgen plc Company Profile (LON:SNG)

About Synairgen plc (LON:SNG)

Synairgen plc logoSynairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: LON:SNG
  • CUSIP: N/A
  • Web:
  • Market Cap: £9.82 million
  • Outstanding Shares: 91,362,000
Average Prices:
  • 50 Day Moving Avg: GBX 8.54
  • 200 Day Moving Avg: GBX 14.16
  • 52 Week Range: GBX 6.98 - GBX 36
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.05 per share
  • Price / Book: 2.15
  • EBIDTA: ($3,410,000.00)
  • Return on Equity: -53.32%
  • Return on Assets: -46.48%
  • Average Volume: 160,576 shs.

Frequently Asked Questions for Synairgen plc (LON:SNG)

What is Synairgen plc's stock symbol?

Synairgen plc trades on the London Stock Exchange (LON) under the ticker symbol "SNG."

Where is Synairgen plc's stock going? Where will Synairgen plc's stock price be in 2017?

0 analysts have issued twelve-month price targets for Synairgen plc's stock. Their predictions range from GBX 46 to GBX 137. On average, they expect Synairgen plc's stock price to reach GBX 91.50 in the next twelve months. View Analyst Ratings for Synairgen plc.

Who are some of Synairgen plc's key competitors?

Who are Synairgen plc's key executives?

Synairgen plc's management team includes the folowing people:

  • John Ward, Finance Director, Executive Director, Secretary
  • Phillip Monk, Chief Scientific Officer, Executive Director
  • Richard Marsden, Chief Executive Officer, Executive Director
  • Simon Shaw, Non-Executive Chairman of the Board
  • Iain Buchanan, Non-Executive Director
  • Bruce L Campbell, Non-Executive Director
  • Paul Hugh Anthony Clegg, Non-Executive Director
  • Stephen Holgate CBE, Non-Executive Director

How do I buy Synairgen plc stock?

Shares of Synairgen plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Synairgen plc's stock price today?

One share of Synairgen plc stock can currently be purchased for approximately GBX 10.75.

MarketBeat Community Rating for Synairgen plc (LON SNG)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Synairgen plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Synairgen plc (LON:SNG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: GBX 91.50

Analysts' Ratings History for Synairgen plc (LON:SNG)
DateFirmActionRatingPrice TargetDetails
9/6/2017N+1 SingerReiterated RatingUnder ReviewView Rating Details
9/6/2017FinnCapReiterated RatingCorporateView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Synairgen plc (LON:SNG)
No earnings announcements for this company have been tracked by


Earnings Estimates for Synairgen plc (LON:SNG)
Current Year EPS Consensus Estimate: $-4.12 EPS


Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synairgen plc (LON:SNG)
Insider Trades by Quarter for Synairgen plc (LON:SNG)
Insider Trades by Quarter for Synairgen plc (LON:SNG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2015Shaw,Simon J BInsiderBuy65,217GBX 23£14,999.91
(Data available from 1/1/2013 forward)


Headline Trends for Synairgen plc (LON:SNG)
Latest Headlines for Synairgen plc (LON:SNG)
DateHeadline logoSynairgen plc (SNG) Rating Reiterated by N+1 Singer - September 6 at 7:20 AM logoSynairgen plc's (SNG) "Corporate" Rating Reaffirmed at FinnCap - August 27 at 3:44 PM logoSynairgen plc (SNG) Rating Reiterated by FinnCap - May 18 at 11:34 PM logoSynairgen plc (SNG) Receives "Corporate" Rating from FinnCap - April 30 at 6:55 PM logoAstraZeneca aims to escape drug sales trough in second half - April 27 at 8:44 AM logoSynairgen plc (SNG) Scheduled to Post Earnings on Monday - March 17 at 11:03 PM logoSynairgen plc (SNG) Given Corporate Rating at FinnCap - March 16 at 4:00 AM logoSynairgen plc (SNG) Stock Rating Reaffirmed by FinnCap - March 10 at 11:10 PM logoSynairgen plc: Additional Positive Data in Lung Fibrosis - March 10 at 8:10 AM logoHalf Year 2016 Synairgen PLC Earnings Release - Before Market Open - September 22 at 12:10 PM logoFull Year 2015 Synairgen PLC Earnings Release - Before Market Open - March 22 at 7:07 AM logoPharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis - August 5 at 12:02 AM


Social activity is not available for this stock.


Synairgen plc (SNG) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff